Catabasis Pharmaceuticals, Inc. Announces Issuance Of Three New US Patents For CAT-1000 Series

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals Inc. today announced that the United States Patent and Trademark Office issued three new patents titled “Fatty acid acetylated salicylates and their uses”, incorporating composition of matter and method of use claims related to the CAT-1000 series of molecules for the treatment of inflammatory disorders. The newly-issued patents are: US 8,729,293, US 8,735,378 and US 8,735,379. The method of use claims in these patents cover multiple inflammatory disease indications, including Duchenne muscular dystrophy (DMD).

Help employers find you! Check out all the jobs and post your resume.